Vertex Pharmaceuticals (VRTX) Restructuring Costs (2009 - 2018)
Vertex Pharmaceuticals (VRTX) posted quarterly Restructuring Costs of -$4000.0 for Q4 2018, down 101.03% year-over-year from $387000.0 in Q4 2017, and down 102.3% quarter-over-quarter from $174000.0 in Q3 2018.
Vertex Pharmaceuticals (VRTX) Restructuring Costs (2009 - 2018) Analysis & Trends
Vertex Pharmaceuticals' Restructuring Costs history runs 10 years deep, the most recent figure standing at -$4000.0 for Q4 2018.
- In Q4 2018, Restructuring Costs fell 101.03% year-over-year to -$4000.0; the TTM figure through Sep 2019 stood at -$4000.0 (down 100.7% YoY), while the FY2018 annual figure was -$184000.0, down 101.29% from the prior year.
- Restructuring Costs for Q4 2018 stood at -$4000.0, down from $174000.0 in the prior quarter.
- The five-year high for Restructuring Costs was $40.8 million in Q3 2014, with the low at -$3.3 million in Q1 2015.
- The 5-year median for Restructuring Costs is $365000.0 (2016), against an average of $3.4 million.
- The sharpest annual moves came in 2014 and 2015: Restructuring Costs soared 15766.67% in 2014, then sank 152.88% in 2015.
- Vertex Pharmaceuticals' Restructuring Costs stood at $4.2 million in 2014, then sank by 63.4% to $1.5 million in 2015, then tumbled by 85.3% to $224000.0 in 2016, then soared by 72.77% to $387000.0 in 2017, then slumped by 101.03% to -$4000.0 in 2018.
- Business Quant data shows VRTX's Restructuring Costs at -$4000.0 in Q4 2018, $174000.0 in Q3 2018, and -$62000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -4,000.00 |
| Sep 30, 2018 | 174,000.00 |
| Jun 30, 2018 | -62,000.00 |
| Mar 31, 2018 | 76,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Sep 30, 2017 | 337,000.00 |
| Jun 30, 2017 | 3.52 Mn |
| Mar 31, 2017 | 10.00 Mn |
| Dec 31, 2016 | 224,000.00 |
| Sep 30, 2016 | 8,000.00 |
| Jun 30, 2016 | 343,000.00 |
| Mar 31, 2016 | 687,000.00 |
| Dec 31, 2015 | 1.52 Mn |
| Sep 30, 2015 | 1.83 Mn |
| Jun 30, 2015 | 2.13 Mn |
| Mar 31, 2015 | -3.27 Mn |
| Dec 31, 2014 | 4.16 Mn |
| Sep 30, 2014 | 40.84 Mn |
| Jun 30, 2014 | -270,000.00 |
| Mar 31, 2014 | 6.19 Mn |